In support of this intervention, recent work demonstrated that JAK inhibitors can ameliorated SS-like manifestations in NOD mice through downregulating IFN pathways.41 Future studies are needed to clarify the pathological connection between IFN signalling and LAMP3 misexpression in patients with SS. Here, LAMP3 is linked to synovial sarcoma.